Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Still a Buy?

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) shares gapped up before the market opened on Thursday . The stock had previously closed at $2.16, but opened at $2.24. Autolus Therapeutics shares last traded at $2.27, with a volume of 119,994 shares trading hands.

Analysts Set New Price Targets

AUTL has been the topic of a number of research analyst reports. Redburn Atlantic raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target on the stock in a research note on Friday, November 15th. The Goldman Sachs Group raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and boosted their target price for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Finally, Needham & Company LLC restated a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, January 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $10.40.

Autolus Therapeutics Stock Up 3.5 %

The business's fifty day moving average is $2.60 and its two-hundred day moving average is $3.51. The stock has a market cap of $630.63 million, a price-to-earnings ratio of -1.96 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period last year, the business posted ($0.26) EPS. As a group, sell-side analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of hedge funds have recently bought and sold shares of AUTL. Exchange Traded Concepts LLC lifted its stake in Autolus Therapeutics by 9.8% in the third quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company's stock worth $152,000 after acquiring an additional 3,740 shares during the last quarter. Bellevue Group AG raised its holdings in shares of Autolus Therapeutics by 27.7% in the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company's stock valued at $151,000 after purchasing an additional 9,000 shares in the last quarter. State Street Corp lifted its position in shares of Autolus Therapeutics by 1.7% during the 3rd quarter. State Street Corp now owns 606,544 shares of the company's stock worth $2,202,000 after purchasing an additional 10,401 shares during the last quarter. ProShare Advisors LLC purchased a new stake in shares of Autolus Therapeutics during the 2nd quarter worth $43,000. Finally, Capstone Investment Advisors LLC acquired a new position in shares of Autolus Therapeutics during the third quarter worth $51,000. Institutional investors and hedge funds own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.